Processes for preparing sunitinib and salts thereof

a technology which is applied in the field of process for the preparation of sunitinib and salt thereof, can solve the problems of toxic, dangerous, expensive reagents,

Inactive Publication Date: 2010-06-24
TEVA PHARMA IND LTD
View PDF12 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

'293 are toxic, dangerous and expensive reagents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Processes for preparing sunitinib and salts thereof
  • Processes for preparing sunitinib and salts thereof
  • Processes for preparing sunitinib and salts thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of sunitinib via 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3Z-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl chloride

[0106]31.2 g of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3Z-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid, obtained as described in U.S. Pat. No. 7,125,905, were refluxed under stirring for 4 hours in one liter flask with 310 g of toluene, 15 g of thionyl chloride and 1 g of dimethylformamide.

[0107]The stirred suspension was cooled at room temperature for 2 hours and filtered; the cake was washed with 50 g of toluene and dried at 50° under vacuum overnight.

[0108]Yield was 32.4 g (97.8%) of a compound corresponding by NMR and MS to the expected structure.

[0109]20 g of diethylendiamine were dissolved in one liter flask with 300 g of tetrahydrofuran; about 200 g of solvent were distilled away at 50° under vacuum.

[0110]20 g of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3Z-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl chloride, prepared as above, were added und...

example 2

Preparation of Sunitinib via 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3Z-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-(carbonyl-1-imidazole)

[0114]4.6 g of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3Z-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid, obtained as described in U.S. Pat. No. 7,125,905, were stirred for 4 hours in 0.1 liter flask with 46 g of 1-methyl-2-pyrrolidone and 3 g of 1,1′-carbonyldiimidazole (CDI), after this time 0.7 g of CDI were added and reaction was left stirring overnight.

[0115]46 g of water were added under stirring and after 1 hour the suspension was filtered and the cake washed with water.

[0116]Product was dried at 60° under vacuum obtaining 5.1 g (95% yield); NMR and MS confirmed the expected structure.

[0117]1 g of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3Z-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-(carbonyl-1-imidazole), prepared as above, was added to 10 g of 1-methyl-2-pyrrolidone and 0.5 g of diethylendiamine under stirring and the mixture was left for one day...

example 3

Conversion of Sunitinib to Sunitinib Malate (According to Example 1, Preparation A of U.S. publication No. 2003 / 0069298)

[0120]Preparation of the Anhydrous Crystal Form I of the L-Malice Acid Salt of N-[2-(Diethylamino) ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide.

Preparation A:

[0121]N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-1-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (130 mg, 0.326 mMol) was added to 20 mL methanol, and the mixture was stirred. L-malic acid (47.2 mg, 0.352 mMol) was added, resulting in rapid dissolution of all the solids. The methanol was removed under reduced pressure to produce a poorly crystalline orange solid. Acetonitrile (5 mL) was added, and the slurry was stirred and heated for about 10 minutes. Stirring was continued while the slurry was allowed to cool to room temperature. The crystals were filtered and dried, resulting in 149 mg of solids (86% yield).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

Methods for preparing sunitinib or salts thereof are described using novel intermediates and chemical pathways. One such intermediate is:

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 12 / 415,352, filed Mar. 31, 2009, which claims the benefit of U.S. Provisional Patent Application Ser. Nos. 61 / 113,044, filed Nov. 10, 2008; 61 / 097,592, filed Sep. 17, 2008; 61 / 094,341, filed Sep. 4, 2008; 61 / 088,998, filed Aug. 14, 2008; 61 / 082,681, filed Jul. 22, 2008; 61 / 082,405, filed Jul. 21, 2008; and 61 / 041,103, filed Mar. 31, 2008, the disclosures of which are hereby incorporated herein by reference.FIELD OF INVENTION[0002]The present invention relates to a process for the preparation of Sunitinib and salt thereof.BACKGROUND OF THE INVENTION[0003]Sunitinib base (“Sunitinib”) of the following formula:is an intermediate for Sunitinib salts, such as Sunitinib malate of the following formula:[0004]Sunitinib malate is marketed under the trade name Sutent® by Pfizer. It is an oral, multi-targeted tyrosine kinase inhibitor used for treatment of various types of cancer.[0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D403/06
CPCC07D403/06A61P35/00A61P43/00
Inventor BIGATTI, ETTORECANAVESI, AUGUSTOMACDONALD, PETER LINDSAYSCARPITTA, FRANCESCA
Owner TEVA PHARMA IND LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap